Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Catalyst?

<< Previous

Bullboard Posts

Next >>

Comment by drippingsnoton Sep 10, 2020 7:14pm

254 Views

Post# 31540101

RE:Catalyst?

Rather than answer that question directly, I would just like to say ... it would thrill me to no end if the stock just halted ... and a buyer for the entire company were announced one day.

No warning.

No share price moves.

Just the stillness of a halted stock under the release of an offer from Big Pharma.

That would be ideal - in my opinion.

: )

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver